Otilimab

Summary

Otilimab (CHEMBL2109433) is a phase-3 clinical-stage antibody; indicated across 4 conditions including rheumatoid arthritis and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109433
Name	Otilimab
Type	Antibody
Max phase	3

Also known as: GSK-3196165, GSK3196165, MOR-103, MOR103, Otilimab, OTILIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
severe acute respiratory syndrome	2	MONDO:0005091	EFO:0000694
osteoarthritis	2	MONDO:0005178	MONDO:0005178
multiple sclerosis	1	MONDO:0005301	MONDO:0005301

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	4
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03970837	PHASE3	TERMINATED	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT03980483	PHASE3	COMPLETED	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
NCT04134728	PHASE3	COMPLETED	Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
NCT04333147	PHASE3	TERMINATED	Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
NCT01023256	PHASE1/PHASE2	COMPLETED	Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis
NCT01517282	PHASE1/PHASE2	COMPLETED	Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
NCT02504671	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis
NCT02683785	PHASE2	COMPLETED	A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis
NCT02799472	PHASE2	COMPLETED	Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis
NCT04376684	PHASE2	COMPLETED	Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
NCT05304130	PHASE1	WITHDRAWN	A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).